Zhengyan Kan
Overview
Explore the profile of Zhengyan Kan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
4975
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Palmer C, Boras B, Pascual B, Li N, Li D, Garza S, et al.
Cancer Cell
. 2025 Mar;
43(3):464-481.e14.
PMID: 40068598
CDK4/6 inhibitors have revolutionized treatment of hormone receptor positive (HR+), HER2 non-amplified (HER2-) breast cancer. Yet, all "dual" CDK4/6 inhibitors show common dose-limiting hematologic toxicities, foremost neutropenia. This poses challenges...
2.
Kan Z, Wen J, Bonato V, Webster J, Yang W, Ivanov V, et al.
Nat Commun
. 2025 Jan;
16(1):932.
PMID: 39843429
To better understand drug resistance mechanisms to CDK4/6 inhibitors and inform precision medicine, we analyze real-world multi-omics data from 400 HR+/HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors plus...
3.
Park Y, Im S, Park K, Wen J, Lee K, Choi Y, et al.
Genome Med
. 2023 Jul;
15(1):55.
PMID: 37475004
Background: Cyclin-dependent kinase 4/6 inhibitor (CDK4/6) therapy plus endocrine therapy (ET) is an effective treatment for patients with hormone receptor-positive/human epidermal receptor 2-negative metastatic breast cancer (HR+/HER2- MBC); however, resistance...
4.
Hooper A, Marquette K, Chang C, Golas J, Jain S, Lam M, et al.
Mol Cancer Ther
. 2022 Jul;
21(9):1462-1472.
PMID: 35793468
Extra domain B splice variant of fibronectin (EDB+FN) is an extracellular matrix protein (ECM) deposited by tumor-associated fibroblasts, and is associated with tumor growth, angiogenesis, and invasion. We hypothesized that...
5.
Freeman-Cook K, Hoffman R, Miller N, Almaden J, Chionis J, Zhang Q, et al.
Cancer Cell
. 2021 Sep;
39(10):1404-1421.e11.
PMID: 34520734
The CDK4/6 inhibitor, palbociclib (PAL), significantly improves progression-free survival in HR/HER2 breast cancer when combined with anti-hormonals. We sought to discover PAL resistance mechanisms in preclinical models and through analysis...
6.
Park Y, Lal S, Lee J, Choi Y, Wen J, Ram S, et al.
Nat Commun
. 2020 Dec;
11(1):6175.
PMID: 33268821
To elucidate the effects of neoadjuvant chemotherapy (NAC), we conduct whole transcriptome profiling coupled with histopathology analyses of a longitudinal breast cancer cohort of 146 patients including 110 pairs of...
7.
Molina-Sanchez P, Ruiz de Galarreta M, Yao M, Lindblad K, Bresnahan E, Bitterman E, et al.
Gastroenterology
. 2020 Aug;
159(6):2203-2220.e14.
PMID: 32814112
Background And Aims: The pattern of genetic alterations in cancer driver genes in patients with hepatocellular carcinoma (HCC) is highly diverse, which partially explains the low efficacy of available therapies....
8.
Tse L, Wang D, Koka H, Zhang T, Abubakar M, Lee P, et al.
Breast Cancer Res
. 2019 Dec;
21(1):147.
PMID: 31856876
Background: Heterogeneity of immune gene expression patterns of luminal breast cancer (BC), which is clinically heterogeneous and overall considered as low immunogenic, has not been well studied especially in non-European...
9.
Kan Z, Ding Y, Kim J, Jung H, Chung W, Lal S, et al.
Nat Commun
. 2018 May;
9(1):1725.
PMID: 29713003
Breast cancer (BC) in the Asia Pacific regions is enriched in younger patients and rapidly rising in incidence yet its molecular bases remain poorly characterized. Here we analyze the whole...
10.
Bourgon R, Dewey F, Kan Z, Li S
Pac Symp Biocomput
. 2017 Dec;
23:1-7.
PMID: 29218864
As the impact of genetics, genomics, and bioinformatics on drug discovery has been increasingly recognized, this session of the 2018 Pacific Symposium on Biocomputing (PSB) aims to facilitate scientific discussions...